Podcasts

Nitin Jain, MD, associate professor in the department of leukemia, University of Texas MD Anderson Cancer Center, is the guest of honor to provide a comprehensive and simplified overview of the major advances in chronic lymphocytic leukemia over the past two decades.

In this pivot episode, James Winterman, Vice President of Scientific Marketing at Caris Life Sciences, joins Chadi as a citizen of England to discuss and reflect on the passing of the late Queen Elizabeth II.

Stacie Dusetzina, PhD, Professor of Health Policy, Ingram Professor of Cancer Research, Vanderbilt University Medical Center, makes her long-awaited return to the show to cover all things related to pharmacy benefit managers.

Tiffany McConathy, an oncology nurse practitioner in Arkansas, tells the sombering story of her infant daughter’s battle with pediatric brain and spinal cancer.

Kyle Kiser, CEO of Arrive Health, joins the show to highlight his company’s unique approach to lowering costs of prescription drugs for patients in the US.

Chadi hosts a duo of Canadiens to discuss quality of life and patient-reported outcomes in clinical trials: Christopher Booth, MD, and Michael Brundage, MSc, FRCPC, MD, both of Queen’s University.

Mike Rucker, PhD, a behavioral scientist and organizational psychologist, joins the show to discuss his writing and publishing of the book “The Fun Habit: How the Pursuit of Joy and Wonder Can Change Your Life.”

How do you design clinical trials in the era of precision oncology? Are prospective randomized controlled trials necessary anymore? Drs. Ray Kurzrock, Vivek Subbiah, and Christopher Booth drop the gloves and debate these questions – beginning with the definition of “precision oncology,” what phase the trials should be when initially designing, and whether accelerated approval and surrogate endpoints are truly helping patients in the precision oncology era.